Friday, July 31st, 2026
Following yesterday’s Personal Consumption Expenditures (PCE) and Wednesday’s Fed meeting an press conference with Fed Chair Kevin Warsh, we quiet down ahead of the final trading session for the week. Despite some mid-week turbulence, we’re trading fairly even with where we were as of mid-day Monday. The Dow is +179 points at this hour, the S&P 500 +12 and the Nasdaq +241 points.
Q2 Employment Costs are out this morning, but unlikely to move the needle in terms of trading sentiment. The headline +0.9% matches the previous quarter and +10 basis points (bps) from expectations. Wages and salaries for civilian workers came in at +3.2%, benefits +3.8%. For state and local government workers, this adjusts to +3.6%.
Q2 Earnings at a Glance: ABBV, XOM & More
AbbVie ABBV shares are trading down at this hour, following a beat by a penny on the bottom line to $3.65 per share on revenues of $16.99 billion, +1.07%. The Big Pharma staple has not missed on earnings since 2018. But full-year earnings guidance was pulled lower than current projections, and shares are down -4% presently. For more on ABBV’s earnings, click here.
A pair of International Integrated Oil & Gas “supermajors” also reported earnings this morning. ExxonMobil XOM posted a negative earnings surprise of -4.35% on lower quarterly oil production, for its second miss in the past four quarter. Chevron CVX beat estimates by +4.48%. Both companies blasted past revenues estimates by +21%, though only Chevron is trading higher.
For more on XOM’s earnings, click here.
For more on CVX’s earnings, click here.
Colgate-Palmolive CL outpaced earnings estimates, $0.99 per share versus $0.95, even though higher tariff costs dampened the household products major’s outlook. Revenues were fairly in-line with estimates at $5.36 billion, above the $5.11 billion reported a year ago. Shares are down -1.8% at this hour. For more on CL’s earnings, click here.
Questions or comments about this article and/or author? Click here>>
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpChevron Corporation (CVX) : Free Stock Analysis Report
ExxonMobil Holdings Corporation (XOM) : Free Stock Analysis Report
Colgate-Palmolive Company (CL) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
